Ciliary neurotrophic factor (CNTF) protects non-obese Swiss mice against type 2 diabetes by increasing beta cell mass and reducing insulin clearance

Diabetologia

Volumn 55, Issue 5, 2012, Pages 1495-1504

  Rezende, L F ^a   Santos, G J ^a   Santos Silva, J C ^a   Carneiro, E M ^a   Boschero, A C ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Alloxan; Beta cell mass; CNTF. IDE; Insulin clearance; Insulin resistance; Insulin secretion; Obesity. Pancreatic islets; Type 2 diabetes

Indexed keywords

ALLOXAN; CILIARY NEUROTROPHIC FACTOR; FATTY ACID; GLUCOSE; INSULIN; INSULIN RECEPTOR; INSULINASE; PROTEIN KINASE B;

ALTERNATIVE RNA SPLICING; ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CELL STRAIN HEPG2; CONTROLLED STUDY; EPIDIDYMIS FAT; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN CLEARANCE; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MOUSE; NEWBORN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; CILIARY NEUROTROPHIC FACTOR; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; EPIDIDYMIS; FATTY ACIDS, NONESTERIFIED; HEP G2 CELLS; HUMANS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; INSULYSIN; MALE; MICE; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, INSULIN;

EID: 84862539606     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-012-2493-5     Document Type: Article

References (50)

1. Chandra J, Zhivotovsky B, Zaitsev S, Juntti-Berggren L, Berggren PO, Orrenius S (2001) Role of apoptosis in pancreatic beta-cell death in diabetes. Diabetes 50(Suppl 1): S44-S47
2. Kotronen A, Juurinen L, Tiikkainen M, Vehkavaara S, Yki-Järvinen H (2008) Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes. Gastroenterology 135: 122-130
3. Anon (1991) Insulin clearance and diabetes. Lancet 338: 1270-1271
4. Valera Mora ME, Scarfone A, Calvani M, Greco AV, Mingrone G (2003) Insulin clearance in obesity. J Am Coll Nutr 22: 487-493
5. Kishimoto T, Akira S, Narazaki M, Taga T (1995) Interleukin-6 family of cytokines and gp130. Blood 86: 1243-1254
6. Febbraio M (2007) gp130 receptor ligands as potential therapeutic targets for obesity. J Clin Invest 117: 841-849
7. Blüher S, Bullen J, Mantzoros CS (2008) Altered levels of adiponectin and adiponectin receptors may underlie the effect of ciliary neurotrophic factor (CNTF) to enhance insulin sensitivity in dietinduced obese mice. Horm Metab Res 40: 225-227
8. Gloaguen I, Costa P, Demartis A et al (1997) Ciliary neurotrophic factor corrects obesity and diabetes associated with leptin deficiency and resistance. Proc Natl Acad Sci U S A 94: 6456-6461
9. Liu QS, Gao M, Zhu SY et al (2007) The novel mechanism of recombinant human ciliary neurotrophic factor on the anti-diabetes activity. Basic Clin Pharmacol Toxicol 101: 78-84
10. Matthews VB, Febbraio MA (2008) CNTF: a target therapeutic for obesity-related metabolic disease? J Mol Med 86: 353-361
11. Ahima R (2006) Overcoming insulin resistance with CNTF. Nat Med 12: 511-512
12. Watt M, Dzamko N, Thomas W et al (2006) CNTF reverses obesity-induced insulin resistance by activating skeletal muscle AMPK. Nat Med 12: 541-548
13. Rezende LF, Vieira AS, Negro A, Langone F, Boschero AC (2009) Ciliary neurotrophic factor (CNTF) signals through STAT3-SOCS3 pathway and protects rat pancreatic islets from cytokineinduced apoptosis. Cytokine 46: 65-71
14. Rezende LF, Stoppiglia LF, Souza KL, Negro A, Langone F, Boschero AC (2007) Ciliary neurotrophic factor promotes survival of neonatal rat islets via the BCL-2 anti-apoptotic pathway. J Endocrinol 195: 157-165
15. Blüher S, Moschos S, Bullen J et al (2004) Ciliary neurotrophic factorAx15 alters energy homeostasis, decreases body weight, and improves metabolic control in diet-induced obese and UCP1-DTA mice. Diabetes 53: 2787-2796
16. Sleeman M, Garcia K, Liu R et al (2003) Ciliary neurotrophic factor improves diabetic parameters and hepatic steatosis and increases basal metabolic rate in db/db mice. Proc Natl Acad Sci U S A 100: 14297-14302
17. Kodama T, Iwase M, Nunoi K, Maki Y, Yoshinari M, Fujishima M (1993) A new diabetes model induced by neonatal alloxan treatment in rats. Diabetes Res Clin Pract 20: 183-189
18. Rafacho A, Cestari TM, Taboga SR, Boschero AC, Bosqueiro JR (2009) High doses of dexamethasone induce increased beta-cell proliferation in pancreatic rat islets. Am J Physiol Endocrinol Metab 296: E681-E689
19. Santos GJ, Oliveira CA, Boschero AC, Rezende LF (2011) CNTF protects MIN6 cells against apoptosis induced by Alloxan and IL-1β through downregulation of the AMPK pathway. Cell Signal 23: 1669-1676
20. Pivovarova O, Gögebakan O, Pfeiffer AF, Rudovich N (2009) Glucose inhibits the insulin-induced activation of the insulindegrading enzyme in HepG2 cells. Diabetologia 52: 1656-1664
21. Ahrén B, Thomaseth K, Pacini G (2005) Reduced insulin clearance contributes to the increased insulin levels after administration of glucagon-like peptide 1 in mice. Diabetologia 48: 2140-2146
22. Steinberg G, Watt M, Fam B et al (2006) Ciliary neurotrophic factor suppresses hypothalamic AMP-kinase signaling in leptinresistant obese mice. Endocrinology 147: 3906-3914
23. Steinberg G, Watt M, Ernst M, Birnbaum M, Kemp B, Jørgensen S (2009) Ciliary neurotrophic factor stimulates muscle glucose uptake by a PI3-kinase-dependent pathway that is impaired with obesity. Diabetes 58: 829-839
24. Hu X, Zhao Y, He X et al (2008) Ciliary neurotrophic factor receptor alpha subunit-modulated multiple downstream signaling pathways in hepatic cancer cell lines and their biological implications. Hepatology 47: 1298-1308
25. Zvonic S, Cornelius P, Stewart WC, Mynatt RL, Stephens JM (2003) The regulation and activation of ciliary neurotrophic factor signaling proteins in adipocytes. J Biol Chem 278: 2228-2235
26. Wadt KA, Larsen CM, Andersen HU, Nielsen K, Karlsen AE, Mandrup-Poulsen T (1998) Ciliary neurotrophic factor potentiates the beta-cell inhibitory effect of IL-1beta in rat pancreatic islets associated with increased nitric oxide synthesis and increased expression of inducible nitric oxide synthase. Diabetes 47: 1602-1608
27. Griffith LC (2004) Calcium/calmodulin-dependent protein kinase II: an unforgettable kinase. J Neurosci 24: 8391-8393
28. Duckworth WC, Bennett RG, Hamel FG (1998) Insulin degradation: progress and potential. Endocr Rev 19: 608-624
29. Strömblad G, Björntorp P (1986) Reduced hepatic insulin clearance in rats with dietary-induced obesity. Metabolism 35: 323-327
30. Hansen BC, Striffler JS, Bodkin NL (1993) Decreased hepatic insulin extraction precedes overt noninsulin dependent (Type II) diabetes in obese monkeys. Obes Res 1: 252-260
31. Rabkin R, Reaven GM, Mondon CE (1986) Insulin metabolism by liver, muscle, and kidneys from spontaneously diabetic rats. Am J Physiol 250: E530-E537
32. Polonsky KS, Given BD, Hirsch L et al (1988) Quantitative study of insulin secretion and clearance in normal and obese subjects. J Clin Invest 81: 435-441
33. Polonsky KS, Gumbiner B, Ostrega D, Griver K, Tager H, Henry RR (1994) Alterations in immunoreactive proinsulin and insulin clearance induced by weight loss in NIDDM. Diabetes 43: 871-877
34. Rudovich N, Pivovarova O, Fisher E et al (2009) Polymorphisms within insulin-degrading enzyme (IDE) gene determine insulin metabolism and risk of type 2 diabetes. J Mol Med 87: 1145-1151
35. Jones CN, Pei D, Staris P, Polonsky KS, Chen YD, Reaven GM (1997) Alterations in the glucose-stimulated insulin secretory dose-response curve and in insulin clearance in nondiabetic insulin-resistant individuals. J Clin Endocrinol Metab 82: 1834-1838
36. Mittelman SD, van Citters GW, Kim SP et al (2000) Longitudinal compensation for fat-induced insulin resistance includes reduced insulin clearance and enhanced beta-cell response. Diabetes 49: 2116-2125
37. Nestler JE, Clore JN, Blackard WG (1988) Reduced insulin clearance in normal subjects due to extreme hyperinsulinemia. Am J Med Sci 295: 15-22
38. Yoshii H, Lam TK, Gupta N et al (2006) Effects of portal free fatty acid elevation on insulin clearance and hepatic glucose flux. Am J Physiol Endocrinol Metab 290: E1089-E1097
39. Wiesenthal SR, Sandhu H, McCall RH et al (1999) Free fatty acids impair hepatic insulin extraction in vivo. Diabetes 48: 766-774
40. Kotronen A, Vehkavaara S, Seppälä-Lindroos A, Bergholm R, Yki-Järvinen H (2007) Effect of liver fat on insulin clearance. Am J Physiol Endocrinol Metab 293: E1709-E1715
41. Fernández-Gamba A, Leal MC, Morelli L, Castaño EM (2009) Insulin-degrading enzyme: structure-function relationship and its possible roles in health and disease. Curr Pharm Des 15: 3644-3655
42. Roeb E, Graeve L, Hoffmann R, Decker K, Edwards DR, Heinrich PC (1993) Regulation of tissue inhibitor of metalloproteinases-1 gene expression by cytokines and dexamethasone in rat hepatocyte primary cultures. Hepatology 18: 1437-1442
43. Rezende AC, Vieira AS, Rogério F et al (2008) Effects of systemic administration of ciliary neurotrophic factor on Bax and Bcl-2 proteins in the lumbar spinal cord of neonatal rats after sciatic nerve transection. Braz J Med Biol Res 41: 1024-1028
44. Vieira AS, Rezende AC, Grigoletto J et al (2009) Ciliary neurotrophic factor infused intracerebroventricularly shows reduced catabolic effects when linked to the TAT protein transduction domain. J Neurochem 110: 1557-1566
45. Leissring MA, Malito E, Hedouin S et al (2010) Designed inhibitors of insulin-degrading enzyme regulate the catabolism and activity of insulin. PLoS One 5: e10504
46. Ettinger MP, Littlejohn TW, Schwartz SL et al (2003) Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: a randomized, dose-ranging study. JAMA 289: 1826-1832
47. van Belle TL, Coppieters KT, von Herrath MG (2011) Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol Rev 91: 79-118
48. Rønn SG, Börjesson A, Bruun C et al (2008) Suppressor of cytokine signalling-3 expression inhibits cytokine-mediated destruction of primary mouse and rat pancreatic islets and delays allograft rejection. Diabetologia 51: 1873-1882
49. Del Prato S, Wishner WJ, Gromada J, Schluchter BJ (2004) Betacell mass plasticity in type 2 diabetes. Diabetes Obes Metab 6: 319-331
50. Rhodes CJ (2005) Type 2 diabetes-a matter of beta-cell life and death? Science 307: 380-384